"The child known as the 'Mississippi baby'—an infant seemingly cured of HIV that was reported as a case study of a prolonged remission of HIV infection in The New England Journal of Medicine last fall—now has detectable levels of HIV after more than two years of not taking antiretroviral therapy without evidence of virus, according to the pediatric HIV specialist and researchers involved in the case.

"'Certainly, this is a disappointing turn of events for this young child, the medical staff involved in the child’s care, and the HIV/AIDS research community,' said NIAID Director Anthony S. Fauci, M.D. 'Scientifically, this development reminds us that we still have much more to learn about the intricacies of HIV infection and where the virus hides in the body. The NIH remains committed to moving forward with research on a cure for HIV infection.'"

More information is available:
"Though combination antiretroviral therapy reduces the concentration of HIV-1 RNA in both plasma and cerebrospinal fluid (CSF) below the detection limit of clinical assays, low levels of HIV-1 RNA are frequently detectable in plasma using more sensitive assays. We examined the frequency and magnitude of persistent low-level HIV-1 RNA in CSF and its relation to the central nervous system (CNS) immune activation. …

"CSF and plasma HIV-1 RNA were measured using the single-copy assay with a detection limit of 0.3 copies/ml in 70 CSF and 68 plasma samples from 45 treated HIV-1-infected patients with less than 40 copies/ml of HIV-1 RNA in both fluids by standard clinical assays. …

"CSF HIV-1 RNA was detected in 12 of the 70 CSF samples (17%) taken after up to 10 years of suppressive therapy, compared to 39 of the 68 plasma samples (57%) with a median concentration of less than 0.3 copies/ml in CSF compared to 0.3 copies/ml in plasma (P<0.0001). …

"Low-level CSF HIV-1 RNA and its association with elevated CSF neopterin highlight the potential for the CNS to serve as a viral reservoir and for persistent infection to cause subclinical CNS injury."

More information is available:
CDC and the Association of Public Health Laboratories (APHL) recently issued Updated Recommendations for Laboratory Testing for the Diagnosis of HIV Infection. This document also offers approaches for reporting test results to people ordering HIV tests and to public health authorities. The recommended algorithm is a sequence of tests used in combination to improve the accuracy of the laboratory diagnosis of HIV based on testing of serum or plasma specimens.

More information is available:
The AIDSinfo and infoSIDA clinical trial search tools make it easy to find HIV/AIDS-related clinical trials. Whether you are searching for trials accepting volunteers, looking for trials in a specific area of interest, or checking for clinical trial results, the search tool makes the job easy.

Use the "Search by Category" menu to browse more than 180 preconfigured searches on a variety of topics. Categories include opportunistic infections, side effects, HIV-related drugs, prevention research, and much more. Once you select your search, you can click the "Refine Search" button on the results page to further tailor your search by attributes such as keyword, recruitment status, study site location, gender, and age.

Our Advanced Search feature allows you to customize your own search. Just enter a keyword in the "Search Term" field (you don't need to add the term "HIV"—your search results will be limited automatically to HIV-related studies) or fill out any other study information field to find a trial.

Please send comments regarding the AIDSinfo or infoSIDA clinical trial search tools to
According to the Centers for Disease Control and Prevention (CDC), about 50,000 people get infected with HIV each year in the United States. However, 1 in 6 people living with HIV don’t know that they are infected. National HIV Testing Day is observed each year on June 27 to highlight the importance of HIV testing.

CDC recommends that everyone between the ages of 13 and 64 get tested for HIV at least once as part of their routine health care. Regardless of age, people at high risk of HIV should get tested more often.

Visit the AIDSinfo National HIV Testing Day webpage [en español] to learn more about HIV testing and to find a testing center near you.
"On June 5, 2014, FDA approved changes to the Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) fixed-dose combination tablet labeling to include rilpivirine dose adjustment information when Complera is coadministered with rifabutin."

The updated labeling for Complera is available at the FDA website.

More information is available:
"On June 2, 2014, FDA approved a new dosage form, Reyataz (atazanavir) oral powder for use in combination with other antiretroviral agents for the treatment of HIV-1, in patients over 3 months of age and between 10 kg to < 25 kg. The first part of this announcement summarizes the changes relevant to the oral formulation and use in pediatric patients. The second part summarizes other general changes to the label."

The updated labeling for atazanavir is available at the FDA website.

More information is available:
The National Library of Medicine (NLM) is pleased to announce the solicitation of quotations from organizations and libraries to design and conduct projects that will improve access to HIV/AIDS-related health information for patients, the affected community, and their caregivers.

Projects must involve one or more of the following information access categories:

  • Information retrieval; 
  • Skills development; 
  • Resource development; and/or 
  • Equipment acquisition.
Emphasis is placed upon the following types of organizations or arrangements for developing these programs:

  • Community-based organizations (CBOs) or patient advocacy groups currently providing HIV/AIDS-related services to the affected community; 
  • Public libraries serving communities in the provision of HIV/AIDS-related information and resources;
  • Health departments or other local, municipal, or state agencies working to improve public health;
  • Faith-based organizations currently providing HIV/AIDS-related services; and/or 
  • Multi-type consortia of the above-listed organizations that may be in existence or formed specifically for this project.
Awards are offered for up to $40,000.

Quotations are due to NLM on Friday, July 11, 2014.

View the solicitation for the 2014 HIV/AIDS Community Information Outreach Projects on the Federal Business Opportunities website. Small businesses can apply to a specific set-aside.

Please Note: Refer to the Federal Business Opportunities website for notices, updates, and modifications to the HIV/AIDS Community Information Outreach Project 2014 request for quotations (RFQ).
On June 8, AIDSinfo joins the nation in observing Caribbean-American HIV/AIDS Awareness Day. This day serves to raise awareness of HIV/AIDS in the Caribbean, a region disproportionately affected by this disease. According to the U.S Agency for International Development (USAID), outside of sub-Saharan Africa, the Caribbean region has the highest HIV prevalence in the world. In addition to raising awareness, the purpose of this day is to provide information and resources about HIV/AIDS to Caribbean Americans.

Explore our Caribbean-American HIV/AIDS Awareness Day webpage [en español] to learn more about the observance and to find information about HIV/AIDS in this region of the world.
News from NIAID

June 2, 2014: Scientists Uncover Features of Antibody-Producing Cells in People Infected with HIV

"By analyzing the blood of almost 100 treated and untreated HIV-infected volunteers, a team of scientists has identified previously unknown characteristics of B cells in the context of HIV infection. B cells are the immune system cells that make antibodies to HIV and other pathogens. The findings augment the current understanding of how HIV disease develops and have implications for the timing of treatment."
News from FDA
"On June 17, 2014, The Forum for Collaborative HIV Research will host an all-day workshop in Washington, DC at the Kaiser Family Foundation's Barbara Jordan Conference Center as part of an ongoing, open process to seek input from the broader HIV community on specific regulatory issues in cure research - such as acceptable risk, ethics, informed consent and appropriate populations.

"The workshop is a collaboration between The Forum, NIH, and FDA, and will involve community, industry and academia."


  • Categories:

    • Locations: